SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy

EBioMedicine. 2021 Nov:73:103635. doi: 10.1016/j.ebiom.2021.103635. Epub 2021 Oct 14.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibodies, Viral / blood
  • Antigens, CD20 / metabolism*
  • COVID-19 / epidemiology
  • COVID-19 / mortality
  • COVID-19 / prevention & control
  • COVID-19 Drug Treatment*
  • COVID-19 Vaccines / immunology
  • Disease Progression
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Multiple Sclerosis / therapy*
  • Rituximab / therapeutic use
  • SARS-CoV-2 / immunology*
  • Vaccination

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Viral
  • Antigens, CD20
  • COVID-19 Vaccines
  • Immunologic Factors
  • Rituximab
  • ocrelizumab

Supplementary concepts

  • COVID-19 breakthrough infections